The company which licensed the Ebola vaccine has announced that human safety trials could start in as early as the next few weeks.
According to Reuters, NewLink Genetics Corp. said that they have enough doses of the vaccine, which was developed by scientists at the Public Health Agency of Canada, to start trials this summer.
NewLink has two contract manufacturing companies and possibly a third, to produce tens of thousands of doses of the vaccine over “the next month or two,” Dr. Charles Link said.
On Tuesday, the World Health Organization endorsed the use of an experimental drug that was sent to Liberia to try and combat the deadly virus.
The Ebola outbreak in West Africa started in March and has been the worst Ebola outbreak in history. The debilitating virus has already claimed the lives of upwards of 1,000 people in Guinea, Liberia, Sierra Leone and Nigeria.
The often fatal virus is also found in primates and spread through close human contact.
Some of the symptoms associated with the virus are arthritis, chills, diarrhea, fatigue, fever, headache, nausea, vomiting and internal as well as external bleeding.
At Large Senior Editor, Temple University graduate, Philadelphia resident and avid sports fan.